DrugPatentWatch Database Preview
Indacaterol maleate - Generic Drug Details
What are the generic sources for indacaterol maleate and what is the scope of patent protection?
Indacaterol maleate
is the generic ingredient in one branded drug marketed by Sunovion Pharms Inc and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.Indacaterol maleate has eighty-five patent family members in thirty-nine countries.
One supplier is listed for this compound.
Summary for indacaterol maleate
| International Patents: | 85 |
| US Patents: | 5 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 32 |
| Clinical Trials: | 24 |
| Patent Applications: | 44 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for indacaterol maleate |
| DailyMed Link: | indacaterol maleate at DailyMed |
Recent Clinical Trials for indacaterol maleate
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Mundipharma Research Limited | Phase 2/Phase 3 |
| Novartis Pharmaceuticals | Phase 4 |
| Novartis Pharmaceuticals | Phase 3 |
Recent Litigation for indacaterol maleate
Identify potential future generic entrants
District Court Litigation
| Case Name | Date |
|---|---|
| Novartis AG v. Lee | 2013-01-14 |
| NOVARTIS AG v. KAPPOS | 2010-07-06 |
Pharmacology for indacaterol maleate
| Drug Class | beta2-Adrenergic Agonist |
| Mechanism of Action | Adrenergic beta2-Agonists |
Synonyms for indacaterol maleate
| (6-((5-fluoro-2-((3,4,5-trimethoxyphenyl)amino)pyrimidin-4-yl)amino)-2,2-dimethyl-3-oxo-2,3-dihydro-4H- pyrido(3,2-b)-1,4-oxazin-4-yl)methyl dihydrogen phosphate |
| (R)-5-(2-(5,6-diethyl-2,3-dihydro-1H-inden-2-ylamino)-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one |
| (R)-5-[2-(5,6-diethyl-indan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-1H-quinolin-2-one |
| (R)-5-[2-(5,6-diethyl-indan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-1H-quinolin-2-one fumarate |
| 1000160-87-1 |
| 2(1H)-Quinolinone, 5-((1R)-2-((5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino)-1-hydroxyethyl)-8-hydroxy-, (2E)-2-butenedioate (1:1) |
| 2(1H)-Quinolinone,5-[(1R)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy- |
| 2474AH |
| 2JEC1ITX7R |
| 312753-06-3 |
| 435273-74-8 |
| 5-(2-(5,6-Diethylindan-2-ylamino)-1-hydroxyethyl)-8-hydroxy-1H-quinolin-2-one |
| 5-[(1R)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy-1,2-dihydroquinolin-2-one |
| 5-[(1R)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy-1H-quinolin-2-one |
| 5-[(1R)-2-[(5,6-Diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy-2(1H)-quinolinone Maleic Acid |
| 5-[(1R)-2-[(5,6-DIETHYL-2,3-DIHYDRO-1H-INDEN-2-YL)AMINO]-1-HYDROXYETHYL]-8-HYDROXYQUINOLIN-2(1H)-ONE |
| 5-[(1R)-2-[(5,6-Diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxyquinolin-2(1H)-one; QAB 149 |
| 5-[(1R)-2-[(5,6-diethylindan-2-yl)amino]-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one |
| 5-[(r)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1h-quinolin-2-one |
| 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one maleate |
| 5-{(1R)-2-((5,6-Diethyl-2,3-dihydro-1H-inden-2-yl)amino)-1-hydroxyethyl}-8-hydroxyquinolin-2(1H)-one |
| 5-{(1R)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl}-8-hydroxyquinolin-2(1H)-one |
| 5-{(1R)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl}-8-hydroxyquinolin-2(1H)-one (2Z)-but-2-enedioate |
| 5,6-diethyl-N-[(2R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl]indan-2-aminium (2Z)-3-carboxyacrylate |
| 753498-25-8 |
| 753I063 |
| 8-Hydroxy-5-[(R)-1-hydroxy-2-(5,6-diethylindan-2-ylamino)-ethyl]-1H-quinolin-2-one |
| 870265-20-6 |
| 8OR09251MQ |
| AB0073003 |
| AB01565805_02 |
| ABP001015 |
| AC-27668 |
| AC-30121 |
| AC1OCFKW |
| AJ-92125 |
| AK163936 |
| AKOS022186691 |
| AKOS024463516 |
| AKOS024464878 |
| AKOS030228638 |
| AN-488 |
| API0008161 |
| Arcapta |
| Arcapta maleate |
| Arcapta Neohaler |
| Arcapta neohaler (TN) |
| AS-10152 |
| AX8161417 |
| BCP03766 |
| BCP0726000140 |
| BCP07503 |
| BCP9000787 |
| BDBM50318159 |
| C24H28N2O3.C4H4O4 |
| CHEBI:68573 |
| CHEBI:68575 |
| CHEMBL1095777 |
| CHEMBL1789842 |
| CS-0744 |
| CS-2703 |
| D09318 |
| D09319 |
| DB05039 |
| DTXSID90185198 |
| FT-0686953 |
| FT-0773084 |
| GTPL7455 |
| Hirobriz Breezhaler |
| HY-14299 |
| HY-14299A |
| I0927 |
| Indacaterol |
| Indacaterol (maleate) |
| Indacaterol (USAN/INN) |
| Indacaterol [USAN:INN:BAN] |
| Indacaterol fumarate |
| Indacaterol maleate (JAN/USAN) |
| Indacaterol maleate [USAN] |
| Indacaterol Maleic Acid Salt |
| IREJFXIHXRZFER-PCBAQXHCSA-N |
| IREJFXIHXRZFER-XRQUGHPZSA-N |
| J-521526 |
| J3BI9P40XE |
| KB-77887 |
| KS-00000SPP |
| MolPort-023-219-171 |
| MolPort-035-395-723 |
| MolPort-044-723-755 |
| Onbrez |
| Onbrez Breezhaler |
| Onbrez Inhalation Capsules |
| Oslif Breezhaler |
| Q-4501 |
| QAB 149 |
| QAB 149 Maleic Acid |
| QAB 149AFA |
| QAB-149 |
| QAB-149 maleate |
| QAB-149-AFA |
| QAB149 |
| QAB149-AFA |
| QABI49 |
| QZZUEBNBZAPZLX-QFIPXVFZSA-N |
| RL03096 |
| S3083 |
| SB20619 |
| SC-90142 |
| SCHEMBL4010239 |
| SCHEMBL48098 |
| SCHEMBL523627 |
| SCHEMBL523629 |
| SW220145-1 |
| UNII-2JEC1ITX7R |
| UNII-8OR09251MQ |
| UNII-J3BI9P40XE |
| W9904 |
| ZINC35801098 |
US Patents and Regulatory Information for indacaterol maleate
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sunovion Pharms Inc | ARCAPTA NEOHALER | indacaterol maleate | POWDER;INHALATION | 022383-001 | Jul 1, 2011 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | ||
| Sunovion Pharms Inc | ARCAPTA NEOHALER | indacaterol maleate | POWDER;INHALATION | 022383-001 | Jul 1, 2011 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | ||
| Sunovion Pharms Inc | ARCAPTA NEOHALER | indacaterol maleate | POWDER;INHALATION | 022383-001 | Jul 1, 2011 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Sunovion Pharms Inc | ARCAPTA NEOHALER | indacaterol maleate | POWDER;INHALATION | 022383-001 | Jul 1, 2011 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for indacaterol maleate
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Taiwan | 200613021 | Start Trial |
| Japan | 3785365 | Start Trial |
| Japan | 4914345 | Start Trial |
| Austria | 440083 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for indacaterol maleate
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1183240 | CA 2010 00006 | Denmark | Start Trial | PRODUCT NAME: INDACATEROL ELLER ET SALT DERAF, HERUNDER INDACATEROLMALEAT |
| 1183240 | SPC/GB10/009 | United Kingdom | Start Trial | PRODUCT NAME: INDACATEROL OR A SALT THEREOF; REGISTERED: UK EU/1/09/593/001 20091130; UK EU/1/09/593/002 20091130; UK EU/1/09/593/003 20091130; UK EU/1/09/593/004 20091130; UK EU/1/09/593/005 20091130; UK EU/1/09/593/006 20091130; UK EU/1/09/593/007 20091130; UK EU/1/09/593/008 20091130; UK EU/1/09/593/009 20091130; UK EU/1/09/593/010 20091130 |
| 1183240 | 91651 | Luxembourg | Start Trial | 91651, EXPIRES: 20241130 |
| 1267866 | 92393 | Luxembourg | Start Trial | PRODUCT NAME: GLYCOPYRRONIUM OU UN SEL DE CELUI-CI, PLUS PARTICULIEREMENT LE SEL BROMURE, COMBINE A INDACATEROL OU UN SEL DE CELUI-CI, PLUS PARTICULIEREMENT LE SEL MALEATE. FIRST REGISTRATION: 20130923 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Copyright 2002-2019 thinkBiotech LLC
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2019 - 2020
NCE-1 Patent Challenge Dates 2019 - 2020
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2019 - 2020
NCE-1 Patent Challenge Dates 2019 - 2020
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2019, www.DrugPatentWatch.com.